Sandip Kapadia
2020 - Intercept Pharmaceuticals
Compensation breakdown
Non-Equity Incentive Plan | $184,039 |
---|---|
Option Awards | $528,088 |
Salary | $476,863 |
Stock Awards | $1,087,836 |
Other | $21,910 |
Total | $2,298,736 |
Kapadia received $1.1M in stock awards, accounting for 47% of the total pay in 2020.
Kapadia also received $184K in non-equity incentive plan, $528.1K in option awards, $476.9K in salary and $21.9K in other compensation.
Rankings
In 2020, Sandip Kapadia's compensation ranked 4,920th out of 13,090 executives tracked by ExecPay. In other words, Kapadia earned more than 62.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 4,920 | 62nd |
Manufacturing | 1,996 | 65th |
Chemicals And Allied Products | 792 | 65th |
Drugs | 683 | 65th |
Pharmaceutical Preparations | 514 | 65th |
Pay ratio
Sandip Kapadia's Pay | $2,298,736 |
---|---|
Median Employee's Pay | $267,493 |
Pay Ratio | 9to 1 |
In 2020, the annual total compensation of Sandip Kapadia was $2,298,736.
The annual total compensation of the median employee at Intercept Pharmaceuticals was $267,493.
The ratio of Sandip Kapadia's pay to the pay of median employee was therefore 9 to one.
Kapadia's colleagues
We found six more compensation records of executives who worked with Sandip Kapadia at Intercept Pharmaceuticals in 2020.
2020
Mark Pruzanski
Intercept Pharmaceuticals
Chief Executive Officer
2020
Jerome Durso
Intercept Pharmaceuticals
Chief Operating Officer
2020
Richard Kim
Intercept Pharmaceuticals
Former President, U.S. Commercial & Strategic Marketing
2020
Lisa Bright
Intercept Pharmaceuticals
Former President, International
2020
Ryan Sullivan
Intercept Pharmaceuticals
General Counsel
2020
Christian MAS
Intercept Pharmaceuticals
EVP, Research & Development
News
May 2, 2022
April 8, 2022
April 27, 2021
April 29, 2020
April 30, 2019